title: Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance.
abstract: Autophagy is an ancient, intracellular degradative system which plays important roles in regulating protein homeostasis and which is essential for survival when cells are faced with metabolic stress. Increasing evidence suggests that autophagy also functions as a tumor suppressor mechanism that harnesses the growth and/or survival of cells as they transition towards a rapidly dividing malignant state. However, the impact of autophagy on cancer progression and on the efficacy of cancer therapeutics is controversial. In particular, although the induction of autophagy has been reported after treatment with a number of therapeutic agents, including imatinib, this response has variously been suggested to either impair or contribute to the effects of anticancer agents. More recent studies support the notion that autophagy compromises the efficacy of anticancer agents, where agents such as chloroquine (CQ) that impair autophagy augment the anticancer activity of histone deacetylase (HDAC) inhibitors and alkylating agents. Inhibition of autophagy is a particularly attractive strategy for the treatment of imatinib-refractory chronic myelogenous leukemia (CML) since a combination of CQ with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) compromises the survival of even BCR-ABL-T315I+ imatinib-resistant CML. Additional studies are clearly needed to establish the clinical utility of autophagy inhibitors and to identify patients most likely to benefit from this novel therapeutic approach.
authors.affiliation: The CTRC Institute for Drug Development, University of Texas Health Science Center San Antonio, San Antonio, TX, USA.
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Carew
authors.forename: Steffan T
authors.initials: ST
authors.lastname: Nawrocki
authors.forename: Francis J
authors.initials: FJ
authors.lastname: Giles
authors.forename: John L
authors.initials: JL
authors.lastname: Cleveland
references.citation: Cancer Res. 2005 Sep 1;65(17):7832-9
references.pmid: 16140952
references.citation: J Cell Biol. 2005 May 9;169(3):425-34
references.pmid: 15866887
references.citation: Cell Death Differ. 2005 Nov;12 Suppl 2:1542-52
references.pmid: 16247502
references.citation: Nat Rev Mol Cell Biol. 2005 Jun;6(6):439-48
references.pmid: 15928708
references.citation: Cancer Res. 2001 Jan 15;61(2):439-44
references.pmid: 11212227
references.citation: Carcinogenesis. 1996 Aug;17(8):1595-607
references.pmid: 8761415
references.citation: Blood. 2007 Jul 1;110(1):313-22
references.pmid: 17363733
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15077-82
references.pmid: 14657337
references.citation: J Exp Med. 2003 May 19;197(10):1323-34
references.pmid: 12756268
references.citation: J Clin Invest. 2007 Feb;117(2):326-36
references.pmid: 17235397
references.citation: Leukemia. 2007 May;21(5):936-42
references.pmid: 17330103
references.citation: J Clin Invest. 2008 Jan;118(1):79-88
references.pmid: 18097482
references.citation: Nat Clin Pract Oncol. 2005 Mar;2(3):150-7
references.pmid: 16264908
references.citation: Nature. 2004 Dec 23;432(7020):1032-6
references.pmid: 15525940
references.citation: J Clin Invest. 2003 Dec;112(12):1809-20
references.pmid: 14638851
references.citation: Science. 2000 Dec 1;290(5497):1717-21
references.pmid: 11099404
references.citation: Cancer Cell. 2002 Aug;2(2):117-25
references.pmid: 12204532
references.citation: Genomics. 1999 Jul 1;59(1):59-65
references.pmid: 10395800
references.citation: Cancer Res. 2003 May 1;63(9):2103-8
references.pmid: 12727826
references.citation: Cancer Res. 2006 Apr 1;66(7):3773-81
references.pmid: 16585204
references.citation: Cancer Res. 2005 Apr 15;65(8):3336-46
references.pmid: 15833867
references.citation: Nature. 1999 Dec 9;402(6762):672-6
references.pmid: 10604474
references.citation: Cancer Biol Ther. 2003 Sep-Oct;2(5):544-51
references.pmid: 14614324
references.citation: Cell. 2005 Jan 28;120(2):237-48
references.pmid: 15680329
references.citation: Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5
references.pmid: 15596714
references.citation: N Engl J Med. 2006 Jun 15;354(24):2531-41
references.pmid: 16775234
references.citation: Proc Natl Acad Sci U S A. 2006 May 9;103(19):7444-9
references.pmid: 16651519
references.citation: Cancer Res. 2005 Apr 15;65(8):2993-5
references.pmid: 15833821
references.citation: N Engl J Med. 2006 Jun 15;354(24):2542-51
references.pmid: 16775235
references.citation: Nat Rev Cancer. 2007 Dec;7(12):961-7
references.pmid: 17972889